MedTrace Logo

Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care

NCT02832297 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2018-07-30

No results posted yet for this study

Summary

In this 12-month multi-center prospective, site-randomized, two-arm trial, approximately 318 biologic-naïve subjects with RA who are candidates for treatment intensification due to inadequate response to MTX monotherapy will be enrolled at up to 60 study sites.

Conditions

  • Arthritis, Rheumatoid

Interventions

OTHER

Vectra DA

OTHER

Usual Care

Sponsors & Collaborators

  • Crescendo Bioscience

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832297 on ClinicalTrials.gov